

Wcont

76. (New) The *Shigella* of claim 74, wherein at least one nucleotide sequence has been inserted into said inactivated *icsA* gene.

77. (New) The *Shigella* of claim 76, wherein a marker gene is inserted into said inactivated *icsA* gene.

78. (New) A vaccine comprising the *Shigella* of claim 74 and a pharmaceutically acceptable vehicle.

79. (New) A *Shigella* comprising an inactivated *icsA* gene, inactivated by allelic exchange with a mutagenized *icsA* gene that has been mutagenized *in vitro*, wherein said mutagenesis is other than only by means of a transposon inserted into the gene.

80. (New) The *Shigella* of claim 79, wherein a marker gene is inserted into said mutagenized *icsA* gene.

81. (New) A vaccine comprising the *Shigella* of claim 79 and a pharmaceutically acceptable vehicle.

82. (New) A *Shigella* comprising an inactivated *icsA* gene, inactivated other than only by means of a transposon inserted into the gene, wherein said *Shigella* does not comprise an active copy of said *icsA* gene.

83. (New) The *Shigella* of claim 82, wherein a marker gene is inserted into said inactivated *icsA* gene.

84. (New) A vaccine comprising the *Shigella* of claim 82 and a pharmaceutically acceptable vehicle.

85. (New) A *Shigella* comprising an inactivated *icsA* gene, inactivated by allelic exchange with a mutagenized *icsA* gene that has been mutagenized *in vitro*, wherein

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, DC 20005
202-408-4000